Phase 2 of the AASK trial is presented here. Phase 1 of the trial showed that the use of ACE-inhibitors in African-American patients with hypertension and minimal proteinuria was superior at preventing the development of ESRD than beta-blockade or use of dihydropyridines. Phase 2 analyzes this data over a 10-year follow-up period.

***Note: Comments about this teaching resource, its content, and your thoughts can be made on this website (by registered users) or on Facebook (all users).

**************************************

Time Required (estimated): 60 minutes
Title: AASK Trial
Author: Sarath Kolluru, MD
Author Type: Fellow
Citation: Nephrology On-Demand 2011
Date Created: 2011
Revisions: None Indicated
Disclaimers: None Indicated
Resource Type: Video
Recommend to a Colleague/Friend
Review this teaching resource below
**************************************

LEARNING OPTIONS:

To view the interactive video, click here
To view this video using an iPad or iPhone, see below

httpv://www.youtube.com/watch?v=tDjyuXc5fsw


Transparent Peer Review
Your reviews are anonymous

[starratingmulti id=”3″]

To learn more about our 6-point transparent peer review system, click here



Share

Comments

You must be logged in to post a comment.

Name

Email

Website

Speak your mind

  • Nephrology On-Demand Plus


    Our full-featured iOS app for the iPhone and iPad. NOD + integrates
    1. kidney education,
    2. training, and
    3. recruitment

    into a streamlined and user-friendly interface.


    Available_on_the_App_Store_(black)

  • Kidney Konnection


    A newsletter that discusses sophisticated topics in Nephrology for physicians in Internal Medicine.
    Click here to access your complimentary subscription